When renal function is impaired, elimination of atenolol is closely related to the glomerular filtration rate; significant accumulation occurs when the creatinine clearance falls below 35 mL/min/1
Atenolol tablets USP, 50 mg (White to off-white marble finish, round, flat beveled edge tablets
It is a white or almost white powder, sparingly soluble in water; soluble in absolute alcohol and practically insoluble in ether
0% and NMT 110
Initially, 50 mg once daily, alone or in combination with a diuretic recommended by manufacturer; full hypotensive effect usually seen within 1–2
Tenormin Descriptions Atenolol is used alone or together with other medicines to treat high blood pressure (hypertension)
Last
Increase to 100 mg orally once a day after 1 week if optimal response not
In standard animal or human pharmacological tests, beta-adrenoreceptor blocking activity of atenolol has been demonstrated by: (1) reduction in resting and exercise heart rate
Atenolol tablets USP are indicated for the treatment of hypertension, to lower blood pressure
See accompanying
When renal function is impaired, elimination of atenolol is closely related to the glomerular filtration rate; significant accumulation occurs when the creatinine clearance falls below 35 mL/min/1
It is freely soluble in 1N HCl (300 mg/mL at 25°C) and less soluble in chloroform (3 mg/mL at 25°C)
The molecular and structural formulas are: Atenolol, USP has a molecular weight of 266
Atenolol is a beta -selective (cardioselective) beta-adrenergic receptor blocking agent without membrane stabilizing or intrinsic sympathomimetic (partial In patients who tolerate the full intravenous dose (10 mg), atenolol tablets 50 mg should be initiated 10 minutes after the last intravenous dose followed by another 50 mg oral dose 12 hours later
Atenolol Tablets USP: Tablets of 50 mg atenolol, NDC 71205-229-30 (circular, biconvex, Atenolol Tablets contain NLT 90
Delivery: from $0 to $12
Following oral doses of 50 mg or 100 mg, both beta-blocking and antihypertensive effects persist for at least 24 hours
In standard animal or human pharmacological tests, beta-adrenoreceptor blocking activity of atenolol has been demonstrated by Atenolol is an additional treatment to standard coronary care unit therapy
We establish primary standards for helping to ensure quality in pharmaceutical development and manufacturing
Each 50 mg atenolol tablet, USP is available as white to off-white round, flat face Each Atenolol and Chlorthalidone Tablet, USP 50 mg/25 mg contains: Atenolol, USP
In standard animal or human pharmacological tests, beta-adrenoreceptor blocking activity of
The 25 mg tablets are white to off-white, round, unscored tablets debossed with A2 on one side of the tablet and M on the other side
Atenolol, a synthetic, beta 1-selective (cardioselective) adrenoreceptor blocking agent, may be chemically described as benzeneacetamide, 4-[2’-hydroxy-3’-[(1-methylethyl)amino]propoxy]-
In standard animal or human pharmacological tests, beta-adrenoreceptor blocking activity of atenolol tablets have been demonstrated by: (1) reduction in resting and exercise heart rate and cardiac output, (2) reduction of systolic and diastolic blood pressure at rest and on exercise, (3) inhibition of isoproterenol induced
> 27